US lawmakers present no evidence of Russia’s interference in US election - Russian MPRussian Politics & Diplomacy February 23, 21:42
Russia to continue strengthen its Armed Forces - PutinRussian Politics & Diplomacy February 23, 21:37
4,000 Russian nationals fight among militants in Syria - PutinRussian Politics & Diplomacy February 23, 21:31
Opposition’s demand of Assad’s immediate resignation absurd - Russian envoy to GenevaRussian Politics & Diplomacy February 23, 16:34
Moscow celebrates Defender of the Fatherland DaySociety & Culture February 23, 16:19
ISS astronauts capture Dragon with manipulatorScience & Space February 23, 14:36
Vitaly Churkin’s body delivered to RussiaRussian Politics & Diplomacy February 23, 12:30
Ukrainian military shell Donetsk water purification plantWorld February 23, 11:45
Scientists discover three Earth-sized exoplanets that may potentially harbor lifeScience & Space February 23, 5:50
TUCSON, Arizona, March 3, 2016 /PRNewswire/ -- HSRx Biopharmaceutical, a leading developer of polyfunctional-powered combination drugs for infectious disease conditions and disease conditions related to aging and lifestyle, and Thorne Research, Inc., a leading personalized health solutions company, today announced that the two companies have executed a collaboration agreement for researching, licensing, and distributing botanical drug products and nutritional supplements.
Logo - http://photos.prnewswire.com/prnh/20160302/339944LOGO
Logo - http://photos.prnewswire.com/prnh/20160302/339943LOGO
"The venture's immediate focus will be the development and rapid roll-out of first-in-class botanical drug products, approved under the U.S. FDA's Botanical Drug Guidelines, for two significant unmet needs for infectious disease," said HSRx's Chief Executive Officer, Thomas Sullivan, Jr. The total U.S. market demand for these two targeted areas is estimated to exceed $2 billion.
Preclinical human safety and efficacy studies have already been completed for HSRx's fully developed and patent-pending food-based botanical drug compounds for the two targeted disease conditions. Thorne Research, which has a Collaborative Research Agreement with Mayo Clinic, will continue the botanical drug development effort by initiating clinical trial development and the subsequent FDA approval process. Thorne Research's Chief Executive Officer, Paul Jacobson, said, "Thorne Research is committed to bringing medical professionals safe and efficacious botanical products for the benefit of patients worldwide. Our collaboration with HSRx significantly advances this effort."
HSRx's proprietary technology identifies in food products and botanical ingredients those bioactive nutrients that demonstrate effectiveness against specific disease conditions. HSRx also identifies – via genomics, proteomics, and metabolomics – the molecular pathways and mechanisms utilized by the bioactive nutrients to deliver health benefits. HSRx precisely monitors quality and purity throughout production and processing. Its proprietary safety screening program can test for more than 1,400 chemical contaminants, representing the most sophisticated and rigorous quality control in the health products industry.
"HSRx can demonstrate dose-consistent biological results for each of its proprietary compounds, which solves the problem of batch inconsistency the FDA has consistently identified as a major issue for botanical-based products," Sullivan said. "Our collaboration with Thorne Research marks the establishment of a new leader in botanical drug development. Together, we have the science, talent, manufacturing capacity, and brand loyalty to assure extraordinary success."
Thorne Research is a personalized health solutions company dedicated to improving individual outcomes through science and technology. For 30 years, Thorne Research has led the industry in providing clinically proven, high quality natural products including foundational vitamins and minerals, therapeutic focused nutritional supplements, and soon to include medical foods and botanical drugs. By leveraging cutting-edge research and personalized data through affiliate WellnessFX, Thorne Research offers customized preventive health solutions for practitioners and their patients. Thorne Research is a majority shareholder in WellnessFX, a San Francisco-based personalized wellness company, providing home kit testing and actionable recommendations from the analysis of blood chemistry, genetics, and microbiome.
Thorne Research is headquartered in New York City with a manufacturing facility in Sandpoint, Idaho. Further information on Thorne Research is available at Thorne.com.
HSRx Biopharmaceutical is an Arizona-based biopharmaceutical company that is a leader in the development of polyfunctional pharmaceuticals, a new advancement in drug treatment therapies. HSRx's combination drugs uniquely target and engage multiple disease condition related molecular targets, not just the single molecular target current drug treatment therapies engage to create drug treatment therapies that treat the entire disease condition, not just a single disease symptom. This orally delivered polyfunctional power is clinically proven to deliver a safer and more effective disease condition treatment therapy for many chronic and infectious disease conditions. HSRx utilizes a proprietary technology to identify and capture the polyfunctional disease fighting nutrients in GRAS-status foods and combines these proprietary compounds with leading FDA-approved generic drugs to create powerful new combination drugs with long patent lives. In clinical studies designed to compare the safety and effectiveness of the HSRx combination drugs with the safety and effectiveness of the current leading generic drug treatment, the polyfunctional-powered HSRx combination drugs demonstrate superior effectiveness with fewer reported side effects. HSRx combination drugs provide medical professionals and their patients with new drug treatment therapies that deliver the polyfunctional solutions needed for many complex disease conditions related to aging and lifestyle. More information is available at HSRxBiopharmaceutical.com
Contact: Matt Russell
Russell Public Communications